

ACCEPTED PAPER · SUPPLEMENTARY FILE

Fabrication of prevascularized co-culture spheroids and their 3D bioprinting application

Paper version: Accepted Paper

Accepted Papers are manuscripts accepted for publication, encompassing all changes made following the peer review process, along with a standard cover page indicating the paper version and an “Accepted Paper” watermark, but excluding any other editing, typesetting or other changes made by AccScience Publishing and/or authors post-acceptance.

Article ID: IJB026270284

Citation: Alt DS, Petsinger VI, Jeon O, Ding A, Alsberg E. Fabrication of prevascularized co-culture spheroids and their 3D bioprinting application. *Int J Bioprint*. 2026. doi: 10.36922/IJB026270284

Copyright: © 2026 Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License, permitting distribution, and reproduction in any medium, provided the original work is properly cited.

Publisher’s Note: AccScience Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Fabrication of prevascularized co-culture spheroids and their 3D bioprinting application

Running title: Prevascularization for 3D bioprinting

Supplementary File

Supplemental results

Given the known donor-to-donor variability of differentiation potential of hMSCs,¹ it is theoretically possible that such a variability exists in their ability to support vasculogenesis as well. Therefore, in the present study, the ability of HUVECs to form prevascular structures with hMSCs from a different donor was evaluated. In aggregates formed from a co-culture of HUVECs and a second hMSC donor, CD31 staining showed that prevascular structures formed and persisted for 28 days when cultured in EGM-2 (Fig S1a). When the aggregates were cultured in EGM-2 or EBM-2 with 100 ng/mL FGF-2, both groups demonstrated extensive prevascular cord and plexus formation as seen in CD31 staining at 7 and 14 days (Fig S1b).

Supplemental discussion

Donor to donor variability is well described for hMSCs for orthopedic tissue engineering processes such as osteogenesis and chondrogenesis. However, less is known about donor-to-donor variability for hMSCs in vasculogenic processes. The current system was used with a second hMSC donor to demonstrate prevascular structure formation and persistence up to 28 days in EGM-2 as well as robust prevascular structure formation in aggregates cultured in either EGM-2 or EBM-2

supplemented with 100 ng/mL FGF-2. These reassuring results do not indicate significant donor to donor variability of hMSCs in the current system and suggest that therapies developed from it might be broadly applicable across the patient population.




Figure S1. Prevascular structure formation with a second hMSC donor. (a) Prevascular structure formation was observed over four weeks of in vitro culture in EGM-2 with a different hMSC donor. (b) Robust prevascular structures were observed over two weeks when aggregates were cultured in either EGM-2 or EBM-2 supplemented with 100 ng/mL of FGF-2. Scale bars are 200 μ m.

References

1. Phinney DG, Kopen G, Righter W, Webster S, Tremain N, Prockop DJ. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. *J Cell Biochem.* 1999;75(3)424-36. doi: 10.1002/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.0.CO;2-8